NovoCure Ltd
NVCR· Nasdaq
NVCRNovoCure Ltd
Filed Feb 22, 2024 · 10-K · 53 days after period end · 0001645113-24-000006
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022 | Q4 2021 | Q4 2020 |
|---|---|---|---|---|
| Revenue | $133.78M | $128.43M | $133.21M | $143.95M |
| Net Income | -$47.08M | -$37.30M | -$26.46M | $4.92M |
| EPS Diluted | — | -$0.36 | -$0.25 | $0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
ended Dec 31, 2023 · filed Feb 22, 2024 · 53 d after period end
